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those of EU and IDF criteria were 91.8% and 86.9% respectively. Similarly the NPV 
was highest for the NCEP criteria followed by the EU (99.3%) and IDF (98.3%) criteria. 
The kappa-statistics showed highest agreement with the NCEP criteria (kappa= 0.90) 
while the IDF (kappa= 0.46) and EU criteria (kappa= 0.33) displayed moderate and 
fair levels of agreement respectively with the WHO criteria. CONCLUSIONS: Our 
findings demonstrate that NCEP criteria displayed best performance parameters 
relative to WHO criteria and may serve as alternative to the WHO criteria when 
comparing other definitions used in older studies to current studies.
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In tHeIr own words: socIal lIstenIng for “real-world BenefIts” 
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OBJECTIVES: The objective of this study was to evaluate “real-world benefit” dis-
cussions from publically available de-identified sources (social media and internet 
forums) that can be obtained through social listening. METHODS: A third party 
vendor collected posts from Facebook and Twitter over the previous year for a variety 
of 15 prescription and over-the-counter (OTC) products. Data vocabularies were 
standardized using a vernacular to MedDRA dictionary for medical conditions and 
a custom curated vernacular dictionary for drugs and OTC products. Next, noise 
was systematically removed via natural language processing and each post was 
characterized as a Mention (drug mentioned but no adverse events) or a Proto AEs 
(potential adverse event mentioned within the context of drug use). Finally, the data 
was de-identified prior to making it available to the research team who then man-
ually reviewed each post and collected “real-world benefit” attributes. RESULTS: 
Overall 2159/7529 (29%) of Mentions and Proto AEs contained “real-world benefit” 
information; of the 2159 posts, 1207 (56%) were positive benefits discussions and 
952 (44 %) discussed lack of effect. Of the positive benefits discussions (N= 1207), 94 
(8%) contained benefit time-to-onset, 28 (2%) contained duration of benefit, 125 (10%) 
indicated partial benefit, 514 (43%) indicated full benefit, 37 (3%) contained benefits 
discussion within the context of cost, 196 (16%) contained benefits discussion within 
the context of adverse events, and 138 (11%) contained benefits information as com-
pared to other treatment options. CONCLUSIONS: Social listening has the potential 
to provide a large amount of information about “real-world benefit” as discussed 
from the consumers’/patients’ perspective. This is the first step in understanding 
how Social Listening can contribute to better characterization of benefit/risk profiles 
using the consumers’ own voice.
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Is tHere an assocIatIon Between PotentIally InaPProPrIate 
PrescrIBIng In tHe elderly and HosPItalIzatIon and mortalIty? a 
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OBJECTIVES: Prevalence of potentially inappropriate prescribing (PIP) of harmful 
medications in the elderly has been widely investigated, but it remains unclear 
whether PIP is predictive of adverse events. Our study objective was to determine 
whether exposure to PIP is linked to increased rates of hospitalization and mortal-
ity. METHODS: We performed a retrospective analysis using the Italian Regione 
Emilia-Romagna (RER) longitudinal administrative healthcare database of all elderly 
patients (≥ 65 years) from 2003 to 2013. The RER database includes de-identified, 
fully-linkable demographic, hospital, and pharmacy claims data for all residents 
in the region. PIP exposure initiated upon the dispensing of a medication that 
“should always be avoided” based on the Maio criteria. To estimate PIP exposure 
we computed the number of days supplied for each medication of interest (using 
Defined Daily Doses) plus 30 days. An exposure period spanned the duration of 
consecutive PIP dispensings. An event, the composite outcome of hospitalization 
or death, was attributed to PIP if it occurred during an exposure period. Rate ratios 
and 95% confidence intervals (CI) were estimated by Poisson generalized estimat-
ing equations modeling. RESULTS: The 1,471,179 elderly individuals living in the 
RER contributed a total of 10,369,120 person-years (PY) of follow-up time and expe-
rienced a total of 1,973,878 events. The unadjusted event rate was 1.572 (95% CI: 
1.562, 1.580) times greater among patients exposed to PIP compared to those not 
exposed (2.87 events/10 PY vs. 1.82 events/10 PY). The unadjusted mortality rate was 
1.473 (95% CI: 1.458, 1.488) times greater with PIP exposure (0.51/10 PY vs. 0.35/10 
PY). CONCLUSIONS: These results indicate that exposure to PIP may be associated 
with higher hospitalization and mortality rates in elderly patients. This analysis, 
using a large cohort of patients, sheds light on the importance of reducing PIP in 
this population.
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OBJECTIVES: Adverse Events (AEs) has proven to be a significant cause of hospi-
tal admissions, with prevalence rate ranging from 6.5-26.1% and this constitute a 
significant problem with serious consequences and a challenge for public health. 
This intensive study is aimed at determining the prevalence of AEsas well as to 
assess the cause, nature, severity, preventability and outcomes in a Nigerian teach-
ing hospital and to determine the class of suspected drugs most commonly impli-
cated. METHODS: A three months observational study of 221 consecutive adult 
patients of the Lagos University Teaching Hospital medical in-patient ward and 
out-patient clinic. Epi-info statistical software, (Version 3.4.3, 2007) was used to 
analyze and determine prevalence, causality, severity and preventability. A sig-
nificance level of p < 0.05 was used. RESULTS: The prevalence of AEs was 17.6% 
(95% CI; 12.9, 23.3) with 30 (79.5%) of these presenting at admission and 8(20.5%) 
developing during hospitalization. The World Health Organization (WHO) causality 
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OBJECTIVES: To make eHealth technology more efficient, particularly for the qual-
ity and safety of care, the French Ministry of Health (DGOS) launched the national 
“Hopital numérique 2012-2017” program, a strategic development plan for the 
modernization of health information technology. The aim of this study was to 
assess the impact of the development of electronic health records (EHR) on the 
accreditation results of French hospitals performed by the HAS (French National 
Authority for Health). METHODS: This retrospective study included all of the acute 
care hospitals accredited between October 2012 and April 2014. Three national data-
bases were used: national accreditation database, oSIS (observatoire des systèmes 
d’information de santé-2012), and IPAQSS (indicateurs pour l’amélioration de la 
qualité et la sécurité des soins-2012). National data were provided by the DGOS and 
HAS, together with methodological support. We developed an ordered Logit model, 
where the polytomous dependent variable was ordered according to the follow-
ing descriptions: full accreditation, recommendation, reservation, or delay in the 
accreditation decision. The independent variables were the proportion of EHR used 
(full, partial, or no EHR); type of hospital (teaching, private non-profit, for-profit, or 
other public hospital); accuracy of the care, with versus without home care hospi-
talization; and geographic region. RESULTS: The study included 679 hospitals; 21% 
had full accreditation, 45% recommendation, 25% reservation, and 9% a delay in 
accreditation. We found that the higher the number of full EHR used, the better the 
accreditation decision (p< 0.001). We also observed that the higher the number of 
partial EHR used, the better the accreditation decision (p= 0.002). Finally, the accredi-
tation decision was also better for for-profit hospitals (p< 0.001), private non-profit 
hospitals (p= 0.005), and in the southeast of France (p= 0.02). CONCLUSIONS: Our 
findings suggest that the development of EHR in acute care hospitals is associated 
with a higher performance in accreditation decisions in France.
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OBJECTIVES: In 1998, the Food and Drug Administration (FDA) Adverse Event 
Reporting System (FAERS) (formerly AERS) was launched by the FDA as a post-
marketing safety surveillance program to capture adverse drug events (ADEs) and 
medication errors. From 1998 to 2005, it was found that the number of serious and 
fatal ADEs reported to the FDA increased by 2.6-fold and 2.7-fold, respectively. The 
purpose of this study was to document current trends in serious and fatal ADE 
reports. METHODS: We conducted a retrospective analysis of the 2006-2011 FAERS 
database. Information on patient demographics, primary suspect drug, outcomes, 
and other variables were obtained from data files. Non-US reports and reports 
from clinical trials were excluded. Outcomes were recoded into three categories: 
death, disability (disability or congenital anomaly), and all other serious outcomes 
(hospitalizations, requiring intervention, or life-threatening, or other serious out-
comes). We determined the number of reports by year, the types and sources of 
reports, and age-wise distribution of serious ADEs. A list of drugs with more than 
1,000 reports of serious ADEs was compiled and subgroups of important drugs 
were identified RESULTS: A total of 245,265 reports of deaths (53,447), disabilities 
(20,305), and other serious outcomes (171,513) were reported representing 206,087 
person-reports. The percentage of reports involving death increased from 17.3% in 
2006 to 27.0% in 2011. Analgesics, antihypertensives, and antipsychotics were the 
most common drugs involved in serious reports of ADEs. Drugs with more than 
1,000 serious reports of ADEs included 2 drugs currently withdrawn from market, 4 
drugs under the FDA Risk Evaluation and Mitigation Strategies (REMS) program, 11 
specialty drugs, 3 biologic drugs, and others. CONCLUSIONS: A substantial number 
of serious ADEs were reported from 2006-2011. Drugs under the REMS program, spe-
cialty drugs, and biologic drugs contribute to a significant number of serious ADEs.
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OBJECTIVES: Numerous diagnostic criteria of the metabolic syndrome exist 
including the recent 2009 World Health Organization definition, criteria for 
National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III), 
International Diabetes Federation (IDF) and European Group for Study of Insulin 
Resistance (EGIR). The multiplicity of definitions makes comparing studies with 
older criteria difficult. Our objective was to compute sensitivity, specificity, posi-
tive (PPV) and negative predictive values (NPV) and level of agreement between 
WHO standard and other definitions to determine which criteria performs best 
when comparing estimates from previous studies. METHODS: The NHANES 2009-10 
and 2011-2012 demographics, examination and laboratory data formed our cohort. 
Prevalence estimates using all criteria were calculated. Sensitivity, specificity, PPV 
and NPV of all criteria keeping the WHO criteria as gold standard were computed. 
Kappa statistics to determine strength of agreement between WHO criteria relative 
to other definitions were estimated. RESULTS: WHO criteria yielded the highest 
prevalence at 22.2% followed by NCEP (19.1%), IDF (9.8%) and EU criteria (6.2%). 
Sensitivity of the NCEP criteria was the highest at 86.2% followed by IDF (38.6%) 
and EU (25.9%) criteria. Specificity of the NCEP criteria was highest at 100% followed 
by EU (99.3%) and IDF (98.3%) criteria. The PPV of the NCEP criteria was 100% while 
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emergency cases were young people under 40 years old. Male patients (53.9%) were 
more than female patients. The frequency of emergency visit is 2.7 average per year, 
male patients get 3.0 visits more than female 2.4 visits. About 33.9% of patients 
at one’s own expense. Diseases in the top five were respiratory disease, trauma, 
digestive system diseases, circulation system disease, urinary diseases, respec-
tively. Respiratory disease was the leading member in the spectrum, accounting 
for 25.5%. Poisoning patients account for 1.6% of all emergency cases. Wounded 
patients mostly centralized from May to August, and the bottom periods of the treat-
ment time appeared in midnight (0:00 – 6:00), accounting for 5.5%. CONCLUSIONS: 
Composition of emergency disease spectrum and characteristics of time distribu-
tion can help to develop new prevention and treatment strategies for improving 
quality and increase efficiency. The treatment for respiratory disease headed the 
list of emergency disease spectrum need to optimize medical resourse utilization 
and process improvement.
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Saggia M.
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OBJECTIVES: To identify the key trends in healthcare spending in Brazil in 
2015. METHODS: Review of the Ministry of Health (for programs), Ministry of 
Planning (for budget) and Workd Bank (for GDP growth) reports as well as recently 
published financial information on Bloomberg and Valor (Brazilian newspaper) on 
Federal and States spending. RESULTS: The economic program established by the 
Brazilian government forecasts growth will return only in 2016. It is worth remem-
bering that in 2014 the GDP growth in Brazil was very close to nil. In 2015, economists 
expect the GDP increase to be below 1%. The Ministry of Health budget in 2014 
was US$ 45.6 billion vs. 2015: US 41.2 billion, a 9.6% reduction caused by increased 
inflation and the devaluation of the Brazilian real against the American dollar. 
Moreover, with the reduction in the price of oil some states, such as Rio de Janeiro, 
might lose US$ 750 million in royalties. In the private setting, ANS, the Federal 
agency that regulates private payers (HMOS, healthcare insurers, etc.), is getting 
ready this year to work on the update of the Minimum Mandatory Coverage List valid 
January 2016 on. In a sector in which 80% of the health plans are either collective 
(unions) or paid by companies, thus, dependent on the expansion of the economy, 
the willingness to pay for the incorporation of new technologies would probably be 
low. CONCLUSIONS: With a struggling economy ahead and consequently smaller 
budgets, not only does the Federal Government foresee adjustments in public 
spending but also do State Governments. Context indicates that dialogue and flex-
ibility among healthcare players will be needed more than ever.
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OBJECTIVES: In 2012, the United States Food and Drug Administration (FDA) created 
a new expedited pathway of “Breakthrough Therapy Designation” (BTD) to enable 
an early approval of therapies which have shown substantial activity in early trials. 
The objective of this study was to assess the comparative effectiveness and pric-
ing of drugs with BTD. METHODS: The data for the number of granted BTDs was 
obtained from FDA.gov. The data for publically disclosed BTDs was obtained from 
sponsor’s press releases. For all products, the information for their mechanism 
of action, type of molecule, trial design, clinical efficacy and safety, and pricing 
and time to approval (for approved products) were obtained from peer-reviewed 
publications, conference abstracts, FDA and sponsor websites. RESULTS: Since the 
establishment of the BTD pathway, 55 products have been granted breakthrough 
therapy designations (2012-2014), of which, 42 have been publically disclosed by the 
manufacturers and 6 have been approved by the FDA. In terms of indications, 43% 
are for cancer, 18% are for genetic diseases and 14% are for Hepatitis C Genotype 
1. The median time to approval for these three drug was ~5 years, significantly 
shorter than the 2012 median time to approval for priority review applications 
(6 years). The price premium was 30-50%, compared to other drugs in the same 
category. The six approved BTDs show 20-30% higher response rates than other 
products in the same category. The other products in the pipeline with established 
comparators show 36%-136% improvement in efficacy (based on active controls or 
previous trials). For approximately half of the products, comparative efficacy can-
not be determined because of no previous evidence for a product with efficacy in 
the targeted indications. CONCLUSIONS: BTD is a promising pathway to shorten 
development time and provides early access, however, the high price could pose 
challenges for payers and patients.
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OBJECTIVES: Demonstrate possible savings by expanding the responsible use of 
OTCs (over-the-counter or nonprescription drugs) in Brazil in the public perspec-
tive. METHODS: Measure the volume and medical costs on public health system 
emergency and usage of OTC medicines. Data were obtained from the DATASUS 
system (030106006), SIGTAP 3.01.1.1.3, and research CHPA / USA January 2012 and 
adopted the premise of 10% OTC in the treatment of common diseases (common 
flu, allergy, and pain), to identify the average ticket cost on OTC consumption were 
used IMS Health of 2013 data and for absenteeism costs were used the Brazilian 
Ministry of work and IBGE data. RESULTS: It was estimated that 8% (5,101,692) of 
all emergency attendances in SUS 2013 resulted in prescriptions that exhibited 
OTC medicines to treat common diseases, at a cost of 56 million,costs related to 
improductible days at BRL 369 million and expenditure in the acquisition of these 
assessment ranking showed that 46.2% of AEs were classified as probable, 35.9% 
possible and 7.9% certain. Based on severity of the AEs, 59.0% were classified as 
moderate 30.8% severe, 5.1% mild and lethal respectively. 87.2% of the AEs were 
assessed as possibly preventable. Assessment of outcomes showed that 94.9% of 
the patients recovered fully while 5.1% died. The organs/systems mostly involved 
in the adverse events were the CNS (headache, dizziness and body pain, 22.1%), 
cutaneous organ (rashes and itching, 19.6%) and respiratory system (Breathlessness 
and cough, 13.5%) Antihypertensives (76.8%), antibiotics (10%), antiretrovirals (7.7%) 
and cholesterol lowering agents (7.7%) were the most commonly implicated classes 
of drugs. CONCLUSIONS: The study shows that AEs constitute a significant cause 
of hospital admissions and a good number will likely develop during hospitaliza-
tion. Intensive monitoring and evaluation of AEs is feasible and will likely provide 
a clearer picture of clinical outcomes.
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OBJECTIVES: Worldwide, the number of disabled individuals is used as a marker for 
population health status because of high morbidity and mortality burden associated 
with disability. Prior studies, which analyzed racial/ethnic disparities in individu-
als with disability, have limitations in regards to population, scope or were limited 
to individuals with chronic condition. The purpose of this study is to determine 
prevalence of disability in different racial/ethnic groups using a standard framework 
for disability. METHODS: A retrospective cross-sectional study design with data 
from 7,993 individuals aged above 21 years from 2012 National Health Interview 
Survey (NHIS) was adopted. Race/ethnicity was categorized into: 1) White; 2) African 
American; 3) Latino and 4) other. Disability was defined based on a standard set 
of questions about mobility, self-care, and cognition from the “Functioning and 
Disability” supplement of 2012 NHIS and it was grouped as: 1) No disability; 2) 
Moderate disability; and 3) Severe disability. Chi-square tests and multinomial logis-
tic regressions were conducted to examine the association between race/ethnicity 
and disability. RESULTS: There were statistically significant racial/ethnic differ-
ences in disability status; 10.2% Whites, 14.8% African Americans, 8.1% Latino, and 
6.7% other racial minorities had severe disability. Without adjustments for socio-
economic status, African Americans were more likely to have severe disability than 
Whites (AOR= 1.56, 95% CI= 1.24, 1.95) and Latinos were less likely to have severe 
disability (AOR = 0.70, 95% CI= 0.55, 0.90). After adjusting for socio-economic status, 
we did not observe statistically significant differences in disability status among 
African Americans and Whites. After adjusting for presence of chronic conditions, 
statistically significant differences in disability status among Latinos and Whites 
disappeared. CONCLUSIONS: Differences in prevalence of disability between 
African Americans and Whites can be partially explained by low socio-economic 
status of African Americans. Improving socio-economic status of African Americans 
may reduce racial disparities in disability prevalence.
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OBJECTIVES: Track the perceptions of key CER stakeholders about the current and 
future effects of CER on evidence generation and application for health care deci-
sions METHODS: Internet and mail survey of health care stakeholders, including 
government, health plans, researchers, human resources specialists, employers, and 
trade organizations, that are influential in or affected by CER; telephone follow-up to 
maximize response. RESULTS: Two-thirds of CER stakeholders say that the current 
CER evidence base is insufficient to support treatment decisions, but 90 percent 
remain committed to the importance of CER. This fifth survey in a series begun in 
2010 found fewer respondents reporting no short-term effects of CER, but more than 
half of respondents believe that substantial improvement in decision-making based 
on CER will occur over the next 5 years. Almost three-fourths of respondents recog-
nize PCORI’s significance in funding and monitoring new research, nearly double the 
level five years ago. Respondents are more positive about research priorities; nearly 
40 percent believe priorities somewhat/adequately reflect treatment choices faced 
by patients and providers, compared to only 22 percent two years ago. Just 9 percent 
believe that processes for interpreting evidence are fully transparent and objective, 
fewer than in the previous three surveys. Only about 25% of respondents report that 
real-world evidence or evidence about variability in individual patient response is 
being used to support treatment decisions. CONCLUSIONS: In successive surveys, 
CER stakeholders continue to look to a five-year horizon for significant effects from 
CER. They generally view the evidence base as incomplete, recognize the key players 
in generating new evidence, and understand the time needed for research in their 
projections of CER’s impact. The relatively scarce use of real-world evidence and 
evidence about patient variability reflects their views about the completeness of 
the evidence base to support treatment decisions.
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OBJECTIVES: This study is to analyze age, disease category, time of emergency treat-
ment and regularity of visiting doctors in order to realize the distribution of disease 
spectrum and epidemiological analysis in emergency department in the top three 
hospital in China. METHODS: To select 29,654 cases in emergency department of 
hospital database of 2013. The top five emergency diseases were studied by ret-
rospective research. Data analysis was performed with STATA software package. 
ncy department in the top three hospital in China. RESULTS: The majority of the 
